The societal impact of early intensified treatment in patients with type 2 diabetes mellitus: Supplementary material
dataset
posted on 2022-09-28, 16:11 authored by Foteini Tsotra, Mathias Kappel, Platon Peristeris, Giovanni Bader, Eva Levi, Nicola Lister, Ankur Malhotra, Dennis A Ostwald<p>Aim: The current study estimates the societal impact of early intensified treatment compared with initial</p>
<p>monotherapy with subsequent treatment intensification in newly diagnosed adults with type 2 diabetes</p>
<p>mellitus in Mexico. Methods: An individual patient-level simulation and a static cohort model were</p>
<p>employed to simulate the treatment pathway and the probability of experiencing complications of</p>
<p>diabetes. The avoided number of events was translated into avoided productivity losses, which were</p>
<p>monetized using wages. Results: Patients on early intensified treatment experienced approximately</p>
<p>13,000 fewer complication events over 10 years. This was translated into a societal impact of $54 million</p>
<p>(USD). Conclusion: Early treatment intensification is likely to be of particular benefit to health outcomes</p>
<p>and productivity losses.</p>
Funding
This work was funded by Novartis Pharma AG. F Tsotra, P Peristeris, E Levi and M Kappel are employees of WifOR institute, an independent economic research institute in Darmstadt, DA Ostwald is the CEO of WifOR institute. G Bader, A Malhotra and N Lister are employees of Novartis.
History
Related Materials
- 1. DOI - Is supplement to The societal impact of early intensified treatment in patients with type 2 diabetes mellitus
